The European Society for Medical Oncology (ESMO) has compiled a detailed response to the European Commission's public consultation draft regarding Implementing Regulation for Joint Clinical Assessments of medical and in vitro diagnostic devices. The 4 key strategic priorities noted in the framework include systematic inclusion of oncology expertise, structured stakeholder involvement, proportional and feasible evidence requirements, and clear and consistent guidance on comparators and outcomes.
To learn more and read the full submission, click here.
No comments:
Post a Comment